DGAP-News: Oxford Immunotec receives 2014 Queen's Award for Enterprise

| Source: EQS Group AG
DGAP-News: Oxford Immunotec /
Oxford Immunotec receives 2014 Queen's Award for Enterprise

21.04.2014 / 11:00


OXFORD, United Kingdom and MARLBOROUGH, Mass., 2014-04-21 11:00 CEST (GLOBE
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it has received
a Queen's Award for Enterprise - the UK's highest accolade in business success. 

The Queen's Awards are designed to recognise and encourage the achievements by
businesses in the UK in the fields of Innovation, International Trade and
Sustainable Development. The awards are made annually by Her Majesty The Queen
and are only given for the highest levels of excellence demonstrated in each

Oxford Immunotec received a prestigious Queen's Award for International Trade
for Continuous Achievement, based on its substantial overseas revenue growth
and commercial success over six years. From 2007 to 2012, Oxford Immunotec grew
its overseas earnings by greater than 1300% through expansion into markets
worldwide including the United States, Japan and China. The Company's
T-SPOT(r).TB test for tuberculosis is now approved for sale in over 50 countries
on five continents. The T-SPOT.TB test helps to diagnose tuberculosis infection
before it has progressed to full-blown disease, allowing treatment of carriers
to prevent further spread of TB infection and disease. 

Commenting on the Company's achievement, Dr Peter Wrighton-Smith, Oxford
Immunotec's Chief Executive Officer, said 'We are delighted and honoured to
have the achievements of the Company recognized by Her Majesty. We look forward
to continuing to expand the countries we serve and in continuing our strong
export-led growth.' 

Notes to Editors:

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT(r) technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's initial product developed using the T-SPOT technology
platform is the T-SPOT.TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market approval from the
Food and Drug Administration, Europe, where it has obtained a CE mark, as well
as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA and the Company's shares are traded on The NASDAQ Global Market

Oxford Immunotec was founded in 2002 to commercialise science originating from
the University of Oxford. The Company now employs over 150 people in the UK,
Continental Europe, US and Japan. 

Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

About The Queen's Award Scheme

The Queen's Awards Scheme, originally known as The Queen's Award to Industry,
was instituted by Royal Warrant in 1965 and the first awards were made in 1966.
HM The Queen makes the Awards on the advice of the Prime Minister who is
assisted by an Advisory Committee that includes representatives of Government,
industry and commerce, and the trade unions. They are announced annually on 21
April, The Queen's birthday, and are only given for the highest levels of
excellence demonstrated in each category. Winners of The Queen's Awards can
expect an invitation to attend a special reception at Buckingham Palace. 

For further information please visit www.queensawards.org.uk.

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding future success of the company. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially. Forward-looking statements are based on current expectations and
assumptions and currently available data and are neither predictions nor
guarantees of future events or performance. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this
presentation. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law. 


For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796

For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: +1 (508) 481-4648

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
News Source: NASDAQ OMX

End of Corporate News


21.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English           
Company:     Oxford Immunotec  
             United Kingdom    
ISIN:        GB00BGFBB958      
End of News    DGAP News-Service  
263900 21.04.2014